Navigation Links
Promising new finding for therapies to treat persistent seizures in epileptic patients
Date:1/16/2013

LOS ANGELES (Jan. 16, 2013) In a promising finding for epileptic patients suffering from persistent seizures known as status epilepticus, researchers reported today that new medication could help halt these devastating seizures. To do so, it would have to work directly to antagonize NMDA receptors, the predominant molecular device for controlling synaptic activity and memory function in the brain.

"Despite the development of new medications to prevent seizures, status epilepticus remains a life-threatening condition that can cause extensive brain damage in the patients that survive these persistent seizures," said David E. Naylor, MD, PhD, a lead researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and corresponding author of the new study. "Our research holds promise for the development of new therapies to treat this devastating condition because we have found a potential new target for medical intervention that should bolster the current standard therapies to treat the acute seizures. It may also prevent the long-term adverse effects of persistent seizure activity on the brain."

The research, reported online in the Neurology of Disease journal, used animal models to assess cellular activity in the brain during persistent seizures. It found that the seizure activity seemed to force the NMDA receptors from the interior to the surface of nerve cells causing their activity to increase by approximately 38%.

"The increased presence of the NMDA receptors on the cell surface during these seizures may explain the successful use of NMDA antagonists medication that inhibits the activity of the NMDA receptors in the brain in the latter stages of a seizure, long after other medications have stopped working," said Dr. Naylor. "We concluded that medications that suppress the activity of the NMDA receptors, in conjunction with other medications, may be successful in stopping persistent seizures. Further research is, of course, needed."


'/>"/>
Contact: Laura Mecoy
lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert  

Related biology news :

1. Promising compound restores memory loss and reverses symptoms of Alzheimers
2. Stanford geoscientist cites critical need for basic research to unleash promising energy sources
3. Alzheimers disease in mice alleviated promising therapeutic approach for humans
4. Stem cells + nanofibers = Promising nerve research
5. Berkeley Lab scientists help develop promising therapy for Huntingtons disease
6. Promising new drug target for inflammatory lung diseases
7. Space research institute awards funding to promising medical products
8. American Health Assistance Foundation announces grants to advance promising vision research
9. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
10. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
11. Ultrasensitive biosensor promising for medical diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Promising new finding for therapies to  treat persistent seizures in epileptic patients
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... SAN DIEGO , Feb. 24, 2017  Aethlon ... the following note authored by its Chairman and CEO, ... address at the Munich Security Conference last Saturday, ... engineered virus could kill more people than nuclear weapons. ... by U.S. and U.K. intelligence agencies, that scientific terrorists ...
(Date:2/24/2017)... Staten Island, NY (PRWEB) , ... February 24, 2017 , ... ... exponential rate. Founded in late 2014, FireflySci had the goal of bringing their ... 2017, that goal continues to shape the path that FireflySci is going on as ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... leading digital health company, and Digital Noema ... and remote patient monitoring, announce they are partnering ... DN Telehealth maximizes collaboration compatibility for ... consultations beyond a physical clinical setting to include ...
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
Breaking Biology Technology: